Radiotherapy Market to Hit USD 9.62 Billion by 2030 with 4.9% CAGR | MarketsandMarkets

DELRAY BEACH, Fla., Dec. 11, 2024 /PRNewswire/ -- The global Radiotherapy market is expected to grow to USD 9.62 Billion by 2030, up from USD 7.21 Billion in 2024, at a CAGR of 4.9% over the forecast period. The focus on use of particle therapy for cancer treatment in hospitals, advancements in radiotherapy treatment technology. Furthermore, rising patient population globally is anticipated to further propel market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=567

Browse in-depth TOC on "Radiotherapy Market"
310 - Tables
56 - Figures
312 - Pages

Moreover, in recent years, the market players are also focusing on providing cost-effective radiotherapy systems due to its growing demand amongst various end users in the market. Also, there is an increasing demand for radiotherapy specially EBRT in the emerging markets. All these factors are expected to drive provide growth opportunities for market players offering radiotherapy market.

Radiotherapy is gaining recognition due to increasing awareness, technological advancements, regulatory requirements, consumer demand for effective cancer treatment. Also, governments in these countries are prioritizing the provision of modern & advanced healthcare services to larger portion of their population. Factors such as improved reimbursement coverage, rapid growth in per-capita healthcare expenditure and increasing public demand for affordable healthcare services are driving the expansion of healthcare products, including oncology devices. This trend is reflected in the overall rise in healthcare expenditure. For example, the World Bank projects global healthcare spending to increase by 5-6% annually through 2030, driven by rising demand for advanced treatments and aging populations. Furthermore, healthcare spending in emerging markets, such as Brazil, India, and South Africa, is expected to grow by over 7% annually, as governments and private sectors prioritize health investments.

In addition to low treatment costs, the markets in developing countries are characterized by the presence of less stringent regulations and data requirements. Also, the regulatory policies in the Asia Pacific are considered to be more adaptive and business-friendly by market players. All these factors are encouraging market players to focus more on emerging markets in the coming years.